Eris Lifesciences stated that its consolidated net profit increased 12 per cent to Rs 101 crore for the third quarter ended December 2021.
The company stated that the revenue stood at Rs 332 crore in the third quarter of the current fiscal as against Rs 310 crore in the year-ago period, Eris Lifesciences said.
''Our focus on building leadership brands in fast-growing therapies coupled with several patent expiration opportunities will enable us to sustain our growth trajectory,'' stated Eris Lifesciences Chairman & Managing Director Amit Bakshi.
(With inputs from PTI)
Navi Mumbai News: PM Modi To Arrive At NMIA With ‘India One’ For Inauguration On October 8; Test Landing Successful
Bombay HC Stays Investigation Into Vidhan Bhavan Brawl, NCP Leader Claims Case Politically Driven
Bombay HC Grants Relief To 2 Youths Disqualified Over Height In CAPF Recruitment
Sambhal Bulldozer Row: AIMIM Chief Asaduddin Owaisi Alleges Injustice, Questions Demolition After Supreme Court Guidelines
